SCHEMBL6776568

SCHEMBL6776568

NC(=O)N=C(N)Nc1cccc(C(=O)NCC(=O)NC#CCCC(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ITGB3 P05106 7/20 0.38
ITGA2B P08514 3/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ITGB1 P05556 5/20 0.37
ITGAV P06756 5/20 0.37
ITGA5 P08648 4/20 0.37
MDM2 Q00987 3/20 0.37
MDM4 O15151 3/20 0.37
EPHX2 P34913 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
GAA P10253 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CYP1A2 P05177 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783139 0.89 HTT (0.42) HTTL3MBTL1SMN1; SMN2ITGB3ITGA2B
SCHEMBL6773948 0.88 ITGB3 (0.43) HTTL3MBTL1SMN1; SMN2ITGB3ITGA2B
SCHEMBL7343782 0.87 ALDH1A1 (0.39) L3MBTL1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL6773426 0.80 MAPK1 (0.45) HTTL3MBTL1SMN1; SMN2KMT2AEPHX2
SCHEMBL6777356 0.79 ITGB1 (0.42) HTTL3MBTL1SMN1; SMN2ITGB1ITGA5
SCHEMBL7340558 0.79 EPHX2 (0.39) HTTL3MBTL1SMN1; SMN2KMT2AEPHX2
SCHEMBL7342958 0.76 KMT2A (0.41) L3MBTL1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL6776555 0.76 ITGB3 (0.45) HTTL3MBTL1ITGB3ITGA2BMEN1
SCHEMBL6783445 0.75 KMT2A (0.40) L3MBTL1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL7347508 0.75 KMT2A (0.44) ITGB3ITGA2BMEN1KMT2AITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP claimed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed